Annual Results Press Conference 2022
Boehringer Ingelheim presents the results of business development and gives an outlook for the coming year.
Search
Boehringer Ingelheim puts patient needs first as reflected in the results of the latest “PatientView”
Boehringer Ingelheim puts patient needs first as reflected in the results of the latest “PatientView” survey
Clinical Trial Demonstrates Positive Top-Line Results Reducing Risk Cardiovascular
Clinical Trial Demonstrates Positive Top-Line Results in Reducing the Risk for Cardiovascular Death or Hospitalisation due to Heart Failure
GlyT1 Phase II results
Boehringer Ingelheim refocuses Gly-T1 inhibition brain research on schizophrenia
Boehringer Ingelheim - Value Through Innovation
Boehringer Ingelheim is one of the world's leading research-driven pharmaceutical companies with 130 years of experience.
Elevating Cardio-Renal-Metabolic Care: Boehringer Ingelheim Imparts Latest Insights to 400 Regional Experts
Boehringer Ingelheim hosted the ‘CRM Summit’ to facilitate exchanges and discussions on the latest advances in the management of cardiovascular, renal, and metabolic diseases to help improve patient outcomes across India, the Middle East and Africa
Ileitis prevention vaccination Lawsonia intracellularis pig
Cause, impact and prevention: Learn the essentials about Ileitis
Empagliflozin Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy
Empagliflozin Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
Boehringer Ingelheim’s ‘CRM 360 Meeting’ Brings Together 300 Medical Experts, Highlighting
Boehringer Ingelheim’s ‘CRM 360 Meeting’ Brings Together 300 Medical Experts, Highlighting the Importance of an Integrated Approach to Treat Type 2 Diabetes
Leading experts shed light on importance of establishing dedicated stroke management centers
Leading experts shed light on importance of establishing dedicated stroke management centers across healthcare facilities
Mechanistic Modeling in Biotherapeutic Drug Development
Mechanistic modeling is revolutionizing biotherapeutic drug development with the goal of getting new medicines to patients faster, more reliably and more cost-effectively.
equine asthma
Fighting Equine Asthma is a crucial step to improving the well-being of many horses worldwide. The right treatment can make a world of difference.
Metabolic Diseases
Metabolic Diseases
GARC Louis Nel interview on global rabies control
GARC’s Executive Director Professor Louis Nel shares what it takes to fight rabies.
Cat vaccination 10 things you should know
Find out how you can keep your feline companion happy and healthy. We’ve answered 10 important questions about cat vaccination, to help you make informed decisions about preserving your cat’s health.
Global Code of Conduct
Boehringer Ingelheim´s Global Code of Conduct
Code of Conduct
Our Code of Conduct sets the ethical standards that guides all our business activities. It´s about all of us. Each individual plays a vital role in bringing the Code of Conduct to live.
Bridging the gap in Generalized Pustular Psoriasis (GPP)
Emmanuelle Clerisme-Beaty, Head of Clinical Development and Medical Affairs, Dermatology, discusses recently published insights from GPP patients.
Prevention of Schizophrenia
Can schizophrenia be prevented?That’s what investigators are hoping to find out, according to scientists attending the American College of Neuropsychopharmacology (ACNP) in Orlando, Florida.[node:body][node:title]
IPF treatment discussions
Listen to Steve Jones (a person living wih IPF) and Dr. Marlies Wijsenbeek (a leading pulmonologist) discuss the importance of treatment discussions in IPF
Benefits of Pradaxa®
Oncology and Cancer Immunology Research
Find out more about our research and development in oncology and cancer immunology.
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
Boehringer Ingelheim today reported a strong performance in 2022
SIRPα Cancer Immunology Research
Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Cardiometabolic Research
Read about our patient-centric approach to cardiometabolic disease research.